Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
As of close of business last night, Arcutis Biotherapeutics Inc’s stock clocked out at $14.4, down -0.48% from its previous closing price of $14.47. In other words, the price has decreased by -$0.48 from its previous closing price. On the day, 1.33 million shares were traded. ARQT stock price reached its highest trading level at $14.58 during the session, while it also had its lowest trading level at $14.25.
Ratios:
To gain a deeper understanding of ARQT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.37 and its Current Ratio is at 3.55. In the meantime, Its Debt-to-Equity ratio is 0.78 whereas as Long-Term Debt/Eq ratio is at 0.77.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on December 30, 2024, initiated with a Buy rating and assigned the stock a target price of $19.
On August 28, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $15.
Mizuho Upgraded its Neutral to Buy on January 03, 2024, whereas the target price for the stock was revised from $4 to $8.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 18 ’25 when Welgus Howard G. sold 10,139 shares for $13.37 per share. The transaction valued at 135,574 led to the insider holds 109,414 shares of the business.
Welgus Howard G. bought 10,139 shares of ARQT for $135,573 on Jun 18 ’25. On Jun 13 ’25, another insider, Heron Patrick J, who serves as the Director of the company, bought 2,646 shares for $13.08 each. As a result, the insider paid 34,610 and bolstered with 27,448 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARQT now has a Market Capitalization of 1716508800 and an Enterprise Value of 1629216768. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.07 while its Price-to-Book (P/B) ratio in mrq is 12.03. Its current Enterprise Value per Revenue stands at 7.655 whereas that against EBITDA is -14.053.
Stock Price History:
The Beta on a monthly basis for ARQT is 1.78, which has changed by 0.54838705 over the last 52 weeks, in comparison to a change of 0.12463009 over the same period for the S&P500. Over the past 52 weeks, ARQT has reached a high of $17.75, while it has fallen to a 52-week low of $7.86. The 50-Day Moving Average of the stock is 3.18%, while the 200-Day Moving Average is calculated to be 13.00%.
Shares Statistics:
It appears that ARQT traded 2.18M shares on average per day over the past three months and 2059370 shares per day over the past ten days. A total of 119.14M shares are outstanding, with a floating share count of 104.80M. Insiders hold about 12.08% of the company’s shares, while institutions hold 98.78% stake in the company. Shares short for ARQT as of 1749772800 were 18643341 with a Short Ratio of 8.57, compared to 1747267200 on 16035003. Therefore, it implies a Short% of Shares Outstanding of 18643341 and a Short% of Float of 19.34.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
